Abstract
With respect to the total cure failure of current drugs used in the treatment of neurodegenerative diseases, alternative strategies are followed. Particularly, neuroprotection approaches are questioned. Metal chelation, antioxidant towards oxidative stress, modulation of the amyloidogenic pathway, MAO-B inhibition, and NMDA receptor antagonism is more or less typical examples. Some of the representative drug candidates with promising neuroprotective features are assessed in clinical trials. Although initial attempts were found hopeful, none of the candidates have been found successful in each required clinical trials, particularly depending on the failures in terms of cognitive enhancement and slowing the progressive characteristics of neurodegenerative diseases. Today, neuroprotection is evaluated using multi-target ligand-based drug design studies. Within this study, the clinical outcomes of these studies, the rationale behind the design of the molecules are reviewed concomitant to the representative drug candidates of each group.
Keywords: Neurodegeneration, neuroprotection, amyloidogenic pathway, monoamine oxidase, iron chelator, antioxidant, cholinesterase, NMDA receptor, nitric oxide.
Current Pharmaceutical Design
Title:The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer’s Disease and Parkinson Disease
Volume: 26 Issue: 4
Author(s): Hayrettin O. Gülcan*Ilkay E. Orhan*
Affiliation:
- Eastern Mediterranean University, Faculty of Pharmacy, Famagusta, TR. North Cyprus, via Mersin 10,Turkey
- Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Etiler, Ankara,Turkey
Keywords: Neurodegeneration, neuroprotection, amyloidogenic pathway, monoamine oxidase, iron chelator, antioxidant, cholinesterase, NMDA receptor, nitric oxide.
Abstract: With respect to the total cure failure of current drugs used in the treatment of neurodegenerative diseases, alternative strategies are followed. Particularly, neuroprotection approaches are questioned. Metal chelation, antioxidant towards oxidative stress, modulation of the amyloidogenic pathway, MAO-B inhibition, and NMDA receptor antagonism is more or less typical examples. Some of the representative drug candidates with promising neuroprotective features are assessed in clinical trials. Although initial attempts were found hopeful, none of the candidates have been found successful in each required clinical trials, particularly depending on the failures in terms of cognitive enhancement and slowing the progressive characteristics of neurodegenerative diseases. Today, neuroprotection is evaluated using multi-target ligand-based drug design studies. Within this study, the clinical outcomes of these studies, the rationale behind the design of the molecules are reviewed concomitant to the representative drug candidates of each group.
Export Options
About this article
Cite this article as:
Gülcan O. Hayrettin *, Orhan E. Ilkay *, The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer’s Disease and Parkinson Disease, Current Pharmaceutical Design 2020; 26 (4) . https://dx.doi.org/10.2174/1381612826666200131103524
DOI https://dx.doi.org/10.2174/1381612826666200131103524 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain
CNS & Neurological Disorders - Drug Targets Designing Peptide Mimetics for the Treatment of Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Growth Factor Changes in Cerebrospinal Fluid of Children with Mental Retardation before and after Neural Precursor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study
Current Drug Delivery The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
Current Neuropharmacology Obesity Promotes Oxidative Stress and Exacerbates Sepsis-induced Brain Damage
Current Neurovascular Research Living without Oxygen: Anoxia-Responsive Gene Expression and Regulation
Current Genomics Monoterpenes as Perspective to Chronic Pain Management: A Systematic Review
Current Drug Targets Overview of Genomic Insights into Chicken Growth Traits Based on Genome- Wide Association Study and microRNA Regulation
Current Genomics Targeting the Prokineticin System to Control Chronic Pain and Inflammation
Current Medicinal Chemistry n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy The Technology Development Studio of the MPI-CBG: An Open Access Cell-Based Screening Facility
Combinatorial Chemistry & High Throughput Screening Madecassic Acid Reduces Fast Transient Potassium Channels and Promotes Neurite Elongation in Hippocampal CA1 Neurons
CNS & Neurological Disorders - Drug Targets LW-AFC, A New Formula Derived from Liuwei Dihuang Decoction, Ameliorates Cognitive Deterioration and Modulates Neuroendocrine-Immune System in SAMP8 Mouse
Current Alzheimer Research Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Aerobic Nitroreduction by Flavoproteins: Enzyme Structure, Mechanisms and Role in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Atomoxetine Protects Against NMDA Receptor-mediated Hippocampal Neuronal Death Following Transient Global Cerebral Ischemia
Current Neurovascular Research Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
Current Neuropharmacology